Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
19%
Ph phase_2
12
75%
Ph phase_3
1
6%

Phase Distribution

3

Early Stage

12

Mid Stage

1

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
3(18.8%)
Phase 2Efficacy & side effects
12(75.0%)
Phase 3Large-scale testing
1(6.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(16)

Detailed Status

Completed16

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (18.8%)
Phase 212 (75.0%)
Phase 31 (6.3%)

Trials by Status

completed16100%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_2

DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00005091
completedphase_1

Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction

NCT00045318
completedphase_2

Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma

NCT00041236
completedphase_2

Chemotherapy in Treating Patients With Prostate Cancer

NCT00004045
completedphase_2

DX-8951f in Treating Patients With Liver Cancer

NCT00004108
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT00005091Phase 2

DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed
NCT00045318Phase 1

Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction

Completed
NCT00041236Phase 2

Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma

Completed
NCT00004045Phase 2

Chemotherapy in Treating Patients With Prostate Cancer

Completed
NCT00004108Phase 2

DX-8951f in Treating Patients With Liver Cancer

Completed
NCT00017212Phase 2

DX-8951f in Treating Patients With Metastatic Stomach Cancer

Completed
NCT00055952Phase 2

Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor

Completed
NCT00005938Phase 2

DX-8951f in Treating Patients With Biliary Cancer

Completed
NCT00023972Phase 3

Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed
NCT00004866Phase 2

DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix

Completed
NCT00004046Phase 2

Chemotherapy in Treating Women With Metastatic Breast Cancer

Completed
NCT00003951Phase 2

DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas

Completed
NCT00004047Phase 1

Chemotherapy in Treating Patients Who Have Hematologic Cancer

Completed
NCT00004060Phase 2

Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer

Completed
NCT00055939Phase 2

Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

Completed
NCT00004212Phase 1

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16